Table 3.
Medical treatment for prosthetic and joint infections
| Q1C1 | Q1C2 | Q2C1 | Q2C2 | Q3C1 | Q3C2 | ||
|---|---|---|---|---|---|---|---|
| Post-operative treatment | Pre-operative documentation | YES | NO | YES | YES | NO | YES |
| Bacteriological documentation | MSSA | MSSA | SAMS | E. faecalis | MSSA | S. agalactiae | |
| Narrow-spectrum antibiotic | 99% (36.25/36.5) | NA | NA | 24% (12/50) | NA | 45% (14/31) | |
| Broad-spectrum antibiotic | 0% | NA | NA | 43% (21.5/50) | NA | 52% (16/31) | |
| Oral antibiotic | Rifampicine + quinolones | 70% (28/40) | 92% (33.5/36.5) | NA | NA | 90% (19/21) | NA |
| Total antibiotic regimen after DAIR | 3 weeks | 6% (2/36) | NA | NA | NA | NA | |
| 4 weeks | 35% (12.5/36) | ||||||
| 6 weeks | 53% (0.5/36) | 26% (6/23.5) | |||||
| 8 weeks | 1% (0.5/36 | ||||||
| 3 months | 3% (1/36) | 68% (16/23.5) | |||||
| Suspensive | NA | 4% (1/23.5) | |||||
DAIR Debridement, Antibiotic and Implant Retention, MSSA Methicillin-susceptible Staphylococcus aureus, NA Not applicable